Myriad Genetics Q2 Adj EPS $(0.08), Inline, Sales $183.50M Miss $187.13M Estimate
Portfolio Pulse from totan@benzinga.com
Myriad Genetics reported Q2 adjusted EPS of $(0.08), in line with analyst consensus, but sales of $183.50M missed the estimate of $187.13M. This represents a 300% decrease in earnings and a 2.34% increase in sales from the same period last year.
August 04, 2023 | 2:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Myriad Genetics' Q2 earnings were in line with estimates, but sales missed expectations. Earnings decreased by 300% YoY, while sales increased by 2.34% YoY.
Myriad Genetics' earnings were in line with estimates, which is a neutral factor. However, the company missed sales estimates, which is a negative factor. Additionally, the company's earnings decreased significantly from the same period last year, which is another negative factor. The increase in sales YoY is a positive factor, but it's outweighed by the negatives.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100